FDA panel to weigh revoking key use of Abbott drug

WASHINGTON ? A panel of advisors to the Food and Drug Administration will consider this week whether to revoke a key indication from Abbott's blockbuster cholesterol drug Trilipix. Trilipix is a fibrate, a drug that lowers blood fats...